Karyopharm Therapeutics saw the highest growth of 0.49% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Karyopharm Therapeutics’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Karyopharm Therapeutics has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 33% filings and 50% grants. The United States(US), Australia(AU), South Korea(KR), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Karyopharm Therapeutics is filings its patents. Among the top granted patent authorities, Karyopharm Therapeutics has 50% of its grants in United States(US) and 50% in Brazil(BR).
Roche could be the strongest competitor for Karyopharm Therapeutics
Patents related to cell & gene therapy and climate change lead Karyopharm Therapeutics's portfolio
Karyopharm Therapeutics has the highest number of patents in cell & gene therapy followed by, climate change and rare diseases. For cell & gene therapy, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Lymphoma related patents lead Karyopharm Therapeutics portfolio followed by viral infections, and psoriasis
Karyopharm Therapeutics has highest number of patents in lymphoma followed by viral infections, psoriasis, wounds, and manufacturing/industrial. For lymphoma, nearly 9% of patents were filed and 4% of patents were granted in Q2 2024.
For comprehensive analysis of Karyopharm Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
